Syschem India [SYSCHEM] vs Aarti Drugs [AARTIDRUGS] Detailed Stock Comparison
Syschem India
BSE
Loading...
Aarti Drugs
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Syschem India wins in 7 metrics, Aarti Drugs wins in 12 metrics, with 0 ties. Aarti Drugs appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Syschem India | Aarti Drugs | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 121.28 | 22.81 | Aarti Drugs |
| Price-to-Book Ratio | 2.51 | 3.14 | Syschem India |
| Debt-to-Equity Ratio | 0.00 | 44.92 | Syschem India |
| PEG Ratio | 0.10 | 0.36 | Syschem India |
| EV/EBITDA | 40.71 | 16.76 | Aarti Drugs |
| Profit Margin (TTM) | 0.49% | 7.80% | Aarti Drugs |
| Operating Margin (TTM) | 1.35% | 10.11% | Aarti Drugs |
| EBITDA Margin (TTM) | 1.35% | 10.11% | Aarti Drugs |
| Return on Equity | 0.50% | 12.28% | Aarti Drugs |
| Return on Assets (TTM) | 0.21% | 6.53% | Aarti Drugs |
| Free Cash Flow (TTM) | $-318.13M | $674.20M | Aarti Drugs |
| Dividend Yield | N/A | 0.22% | N/A |
| 1-Year Return | 12.10% | -14.34% | Syschem India |
| Price-to-Sales Ratio (TTM) | 0.59 | 1.77 | Syschem India |
| Enterprise Value | $2.28B | $49.56B | Aarti Drugs |
| EV/Revenue Ratio | 0.56 | 2.05 | Syschem India |
| Gross Profit Margin (TTM) | 5.24% | 36.77% | Aarti Drugs |
| Revenue per Share (TTM) | $104 | $265 | Aarti Drugs |
| Earnings per Share (Diluted) | $0.46 | $20.65 | Aarti Drugs |
| Beta (Stock Volatility) | -0.86 | 0.21 | Syschem India |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Syschem India vs Aarti Drugs Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Syschem India | 6.80% | 18.25% | 19.93% | 29.14% | 26.80% | 13.03% |
| Aarti Drugs | 2.56% | -4.13% | -10.00% | 1.76% | 27.10% | 6.05% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Syschem India | 12.10% | 34.92% | 847.20% | 669.52% | 307.23% | -23.05% |
| Aarti Drugs | -14.34% | 10.27% | -34.08% | 237.25% | 2,680.94% | 2,426.41% |
Performance & Financial Health Analysis: Syschem India vs Aarti Drugs
| Metric | SYSCHEM | AARTIDRUGS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹2.43B | ₹42.99B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 113,037 | 149,023 |
| 90 Day Avg. Volume | 60,692 | 593,839 |
| Last Close | ₹55.79 | ₹483.05 |
| 52 Week Range | ₹35.33 - ₹57.90 | ₹312.00 - ₹635.00 |
| % from 52W High | -3.64% | -23.93% |
| All-Time High | ₹149.00 (Mar 03, 2003) | ₹1,026.95 (Oct 05, 2020) |
| % from All-Time High | -62.56% | -52.96% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.24% | 0.06% |
| Quarterly Earnings Growth | 11.24% | 0.62% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.08% |
| Operating Margin (TTM) | 0.01% | 0.10% |
| Return on Equity (TTM) | 0.01% | 0.12% |
| Debt to Equity (MRQ) | 0.00 | 44.92 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹22.21 | ₹149.84 |
| Cash per Share (MRQ) | ₹0.49 | ₹2.48 |
| Operating Cash Flow (TTM) | ₹-314,030,000 | ₹2.83B |
| Levered Free Cash Flow (TTM) | ₹4.60M | ₹1.68B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.22% |
| Last 12-Month Dividend | N/A | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Syschem India vs Aarti Drugs
| Metric | SYSCHEM | AARTIDRUGS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 121.28 | 22.81 |
| Forward P/E | N/A | 14.86 |
| PEG Ratio | 0.10 | 0.36 |
| Price to Sales (TTM) | 0.59 | 1.77 |
| Price to Book (MRQ) | 2.51 | 3.14 |
| Market Capitalization | ||
| Market Capitalization | ₹2.43B | ₹42.99B |
| Enterprise Value | ₹2.28B | ₹49.56B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.56 | 2.05 |
| Enterprise to EBITDA | 40.71 | 16.76 |
| Risk & Other Metrics | ||
| Beta | -0.86 | 0.21 |
| Book Value per Share (MRQ) | ₹22.21 | ₹149.84 |
Financial Statements Comparison: Syschem India vs Aarti Drugs
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SYSCHEM | AARTIDRUGS |
|---|---|---|
| Revenue/Sales | ₹1.09B | ₹6.77B |
| Cost of Goods Sold | ₹1.04B | ₹4.37B |
| Gross Profit | ₹57.27M | ₹2.40B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹17.08M | ₹784.50M |
| EBITDA | ₹24.69M | ₹951.90M |
| Pre-Tax Income | ₹16.74M | ₹711.50M |
| Income Tax | ₹0 | ₹83.80M |
| Net Income (Profit) | ₹16.74M | ₹627.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SYSCHEM | AARTIDRUGS |
|---|---|---|
| Cash & Equivalents | ₹21.37M | ₹45.80M |
| Total Current Assets | ₹1.61B | ₹13.38B |
| Total Current Liabilities | ₹1.24B | ₹8.37B |
| Long-Term Debt | ₹0 | ₹2.86B |
| Total Shareholders Equity | ₹912.88M | ₹13.69B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹531.11M | ₹8.59B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SYSCHEM | AARTIDRUGS |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SYSCHEM | AARTIDRUGS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 113,037 | 149,023 |
| Average Daily Volume (90 Day) | 60,692 | 593,839 |
| Shares Outstanding | 43.51M | 91.27M |
| Float Shares | 17.38M | 35.46M |
| % Held by Insiders | 0.64% | 0.61% |
| % Held by Institutions | 0.00% | 0.11% |
Dividend Analysis & Yield Comparison: Syschem India vs Aarti Drugs
| Metric | SYSCHEM | AARTIDRUGS |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹1.00 |
| Last 12-Month Dividend Yield | N/A | 0.22% |
| 3-Year Avg Annual Dividend | N/A | ₹1.00 |
| 3-Year Avg Dividend Yield | N/A | 0.23% |
| 3-Year Total Dividends | N/A | ₹3.00 |
| Ex-Dividend Date | N/A | Feb 04, 2025 |